August 10, 2018 10:53 AM EDT

PARP inhibitors for ALS? Penn researchers post promising finds in brain disease

Amber Tong

As a cancer drug, PARP inhibitors have inspired blockbuster projections for drugmakers like AstraZeneca and Pfizer. What if they can also treat brain diseases? …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PARP inhibitors for ALS? Penn researchers post promising finds in brain disease

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Small personalized vaccine trial sees progress in late-stage kidney cancer

GSK defiant against vaccine challenges, will prioritize other growth areas

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

PARP in­hibitors for ALS? Penn re­searchers post promis­ing finds in brain dis­ease

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

PARP inhibitors for ALS? Penn researchers post promising finds in brain disease